Elise A Olsen1, Janet Roberts2, Leonard Sperling3, Antonella Tosti4, Jerry Shapiro5, Amy McMichael6, Wilma Bergfeld7, Valerie Callender8, Paradi Mirmirani9, Ken Washenik10, David Whiting11, George Cotsarelis12, Maria Hordinsky13. 1. Duke University Medical Center, Durham, North Carolina. Electronic address: elise.olsen@dm.duke.edu. 2. Northwest Dermatology and Research Center, Portland, Oregon. 3. HCT Pathology Services, Baltimore, Maryland. 4. University of Miami, Miami, Florida. 5. New York University, New York, New York. 6. Wake Forest Baptist Health Medical Center, Winston-Salem, North Carolina. 7. Cleveland Clinic, Cleveland, Ohio. 8. Howard University College of Medicine, Washington, DC. 9. The Permanente Medical Group, Vallejo, California. 10. New York University, New York, New York; Bosley Medical Group, Beverly Hills, California. 11. Baylor Hair Research Center, Dallas, Texas. 12. University of Pennsylvania, Philadelphia, Pennsylvania. 13. University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: Although alopecia areata is a common disorder, it has no US Food and Drug Administration-approved treatment and evidence-based therapeutic data are lacking. OBJECTIVE: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. METHODS: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. RESULTS: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. LIMITATIONS: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. CONCLUSION: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.
BACKGROUND: Although alopecia areata is a common disorder, it has no US Food and Drug Administration-approved treatment and evidence-based therapeutic data are lacking. OBJECTIVE: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. METHODS: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. RESULTS: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. LIMITATIONS: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. CONCLUSION: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.
Authors: Fanni Adél Meznerics; Kata Illés; Fanni Dembrovszky; Péter Fehérvári; Lajos Vince Kemény; Kata Dorottya Kovács; Norbert Miklós Wikonkál; Dezső Csupor; Péter Hegyi; András Bánvölgyi Journal: Biomedicines Date: 2022-07-29
Authors: K W Wyrwich; H Kitchen; S Knight; N V J Aldhouse; J Macey; F P Nunes; Y Dutronc; N Mesinkovska; J M Ko; B A King Journal: Br J Dermatol Date: 2020-04-03 Impact factor: 9.302